Ascentage Pharma Plans Multiple Trial Presentations at ASH 2026
The company says it will present data from multiple trials, including an oral presentation of APG-5918, at ASH 2026.
Related stories
Toyota Motor shares rise 7.4%
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
Global market picture: S&P 500 +1.65%, Nasdaq 100 +0.72%; EUR/USD +0.41%, WTI -8.05%
Global market picture. US index futures: S and P futures is up 1.65 percent, Nasdaq futures is up 0.72 percent, Dow futures is up 3.14 percent and Russell futures is up 1.48 percen
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
South Korea’s KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC
KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC
NAB Full-Year Cash Profit Misses Estimates as Provisions Rise
Australia's NAB reported full-year cash profit below estimates and higher provisions.
M impact | EQUITY | Nov 04, 2026, 11:59 PM UTC
Nikkei Futures Rise 1.2% to 63,195 on SGX
Japanese stocks may rise after oil fell sharply. The dollar was at 158.39 yen.
M impact | EQUITY | Nov 04, 2026, 11:44 PM UTC